Relative risks of second relapse, treatment failure, and overall mortality
. | Early relapse (<36 mo) . | . | . | Late relapse (≥36 mo) . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome . | N1/N2 . | RR (95% CI) . | P . | N1/N2 . | RR (95% CI) . | P . | ||||
| Leukemia recurrence | ||||||||||
| Chemotherapy | 76/110 | 1.00 | < .001* | 23/78 | 1.00 | < .001* | ||||
| TBI regimen | 41/92 | 0.49 (0.33-0.71) | < .001 | 16/61 | 0.92 (0.49-1.70) | .78 | ||||
| Non-TBI regimen | 15/19 | 1.33 (0.78-2.25) | .29 | 4/14 | 2.49 (1.21-5.10) | .01 | ||||
| Treatment failure | ||||||||||
| Chemotherapy | 85/110 | 1.00 | < .001* | 32/78 | 1.00 | < .001* | ||||
| TBI regimen | 50/92 | 0.55 (0.39-0.79) | < .001 | 24/61 | 1.10 (0.66-1.84) | .70 | ||||
| Non-TBI regimen | 17/19 | 1.56 (0.92-2.48) | .06 | 9/14 | 3.11 (1.72-5.62) | < .001 | ||||
| Overall mortality | ||||||||||
| Chemotherapy | 77/110 | 1.00 | < .001* | 26/78 | 1.00 | < .001* | ||||
| TBI regimen | 48/92 | 0.58 (0.41-0.83) | .003 | 22/61 | 1.21 (0.70-2.07) | .49 | ||||
| Non-TBI regimen | 15/19 | 1.51 (0.94-2.43) | .09 | 9/14 | 3.14 (1.68-5.85) | < .001 | ||||
. | Early relapse (<36 mo) . | . | . | Late relapse (≥36 mo) . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome . | N1/N2 . | RR (95% CI) . | P . | N1/N2 . | RR (95% CI) . | P . | ||||
| Leukemia recurrence | ||||||||||
| Chemotherapy | 76/110 | 1.00 | < .001* | 23/78 | 1.00 | < .001* | ||||
| TBI regimen | 41/92 | 0.49 (0.33-0.71) | < .001 | 16/61 | 0.92 (0.49-1.70) | .78 | ||||
| Non-TBI regimen | 15/19 | 1.33 (0.78-2.25) | .29 | 4/14 | 2.49 (1.21-5.10) | .01 | ||||
| Treatment failure | ||||||||||
| Chemotherapy | 85/110 | 1.00 | < .001* | 32/78 | 1.00 | < .001* | ||||
| TBI regimen | 50/92 | 0.55 (0.39-0.79) | < .001 | 24/61 | 1.10 (0.66-1.84) | .70 | ||||
| Non-TBI regimen | 17/19 | 1.56 (0.92-2.48) | .06 | 9/14 | 3.11 (1.72-5.62) | < .001 | ||||
| Overall mortality | ||||||||||
| Chemotherapy | 77/110 | 1.00 | < .001* | 26/78 | 1.00 | < .001* | ||||
| TBI regimen | 48/92 | 0.58 (0.41-0.83) | .003 | 22/61 | 1.21 (0.70-2.07) | .49 | ||||
| Non-TBI regimen | 15/19 | 1.51 (0.94-2.43) | .09 | 9/14 | 3.14 (1.68-5.85) | < .001 | ||||
N1 indicates number of events; N2, number evaluable.
Two-degree freedom test.